Science and Uncertainty: Valuation in the Bio-Medical Industry
Valuation is often said to be “an art, not a science” in recognition of the uncertainties involved. The valuation of biomedical companies, though science-based businesses, is no less susceptible to uncertainty. Indeed, the biomedical industry is riskier than many other industries due to the particular regulatory and economic factors involved. Ignoring these factors may result in the doctor calling a “code blue” on your valuation. Join technology and valuation expert John Elmore in a discussion of cogent approaches and methods for valuing biomedical company assets and business interests for financial reporting, taxation, litigation, and other purposes. This session will summarize the economic and regulatory environment of the biomedical industry and address how valuation analysts can model the complexities and uncertainties inherent to the industry.
IMPORTANT: Each Training Pack includes an MP4 video file, MP3 audio file, complete transcript, slide presentation in PDF format, and additional reading materials when available. Please note that Training Packs can take up to 4 weeks after the webinar to complete. Once available you will receive an email with a special link to download your Training Pack. If you are ordering a Training Pack after the 4 week window, the download link will be sent to you immediately via email. Please check your spam folder and add email@example.com to your "safe list" to ensure you receive your Training Pack.